Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Compugen Signs Novartis to Multimillion Dollar LEADS License

NEW YORK, Aug. 2 – Compugen has licensed its LEADS computational biology platform to Novartis, the company announced on Thursday.

The deal, which will run for one year with the option for Novartis to extend two additional years, also includes a proprietary DNA chip design to represent Novartis’ transcriptome database. The deal is worth a "few million dollars" Compugen CEO Mor Amitai told GenomeWeb.

"For us this is a big deal," said Amitai. "Financially, it is substantial, and it [also] means working with one of the best functional genomics groups in the world. It is an imporant validation for us and our technologies." Amitai added that the agreement would allow Compugen to improve its tools based on Novartis' feedback.

The LEADS bioinformatics platform incorporates genomics and proteomics tools and public and proprietary databases. Other licensees include Human Genome Sciences and Pfizer.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.